Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Planned appointment of joint broker and change of nominated adviser

December 20, 2018
Download  full announcement   Renalytix AI plc (AIM: RENX), a developer of artificial intelligence (“AI”) enabled clinical diagnostics solutions for kidney disease, notes the announcement today by EKF Diagnostics Holdings plc (AIM: EKF) and confirms that it has agreed a different resolution to the

Director Dealing

December 19, 2018
Download  full announcement   The Company was informed that today, Christopher Mills, a non-executive director, completed the purchase of 5,970 ordinary shares of 0.25 pence each (“Ordinary Shares”) in the Company at a price of 103 pence per share. Following this purchase, Mr Mills is interested in

TR-1: Standard form for notification of major holdings

December 14, 2018
Download  full announcement   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer  and  to the FCA in Microsoft Word format if possible) i   1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Renalytix AI Plc 1b.

TR-1: Standard form for notification of major holdings

November 9, 2018
Download  full announcement   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer  and  to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii :   Renalytix AI Plc   (LEI:

Director / PDMR shareholding

November 8, 2018
Download  full announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence (“AI”) enabled clinical diagnostic solutions for kidney disease, announces that it was yesterday notified that on 6 November 2018 the following PDMR undertook a transaction in the ordinary shares of

TR-1: Standard form for notification of major holdings

November 8, 2018
Download  full announcement NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer  and  to the FCA in Microsoft Word format if possible) i   1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Renalytix AI PLC 1b.

Update regarding AIM admission of RenalytixAI

November 1, 2018
Download  full announcement Renalytix AI plc, which develops artificial intelligence (“ AI ”) enabled clinical decision support solutions for kidney disease, announces that, further to the announcement by EKF Diagnostics Holdings plc  (“EKF”)  on 31 October confirming that RenalytixAI’s had

RENX Launch of Restricted Offer

October 11, 2018
THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY AND RENALYTIX AI PLC TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER ARTICLE 7 OF REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO

RENX Pricing announcement

October 11, 2018
THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY RENALYTIX AI PLC TO CONSTITUTE INSIDE INFORMATION IN RELATION TO THE COMPANY’S QUOTED SECURITIES AS STIPULATED UNDER ARTICLE 7 OF REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE,
Displaying 171 - 180 of 183